Minimum infective dose of HIV for parenteral dosimetry

International Journal of STD and AIDS

Volumn 20, Issue 12, 2009, Pages 828-833

  Reid, S ^a   Juma, O A ^b  

^a UNIVERSITY OF NEVADA   (United States)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Africa; HIV; Iatrogenic; Nosocomial; Parenteral

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; VIRUS DNA; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; AUTOCLAVE; CD4+ T LYMPHOCYTE; CONTAMINATION; DOSIMETRY; EXPOSURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INFECTION RISK; INJECTION; INOCULATION; INSTRUMENT STERILIZATION; MINIMUM INFECTIVE DOSE; NEEDLESTICK INJURY; NONHUMAN; PATIENT SAFETY; PHLEBOTOMY; PRIMARY INFECTION; PRIORITY JOURNAL; PROBABILITY; REVIEW; RISK FACTOR; SEROCONVERSION; SIMULATION; SURVIVAL; SYRINGE; VIRION; VIRUS INFECTIVITY; VIRUS LOAD; VIRUS STRAIN; VIRUS TRANSMISSION;

ANIMALS; CROSS INFECTION; EQUIPMENT CONTAMINATION; EQUIPMENT REUSE; HIV INFECTIONS; HIV-1; HUMANS; IATROGENIC DISEASE; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAVENOUS; NEEDLESTICK INJURIES; RISK ASSESSMENT; SYRINGES; VIRAL LOAD;

EID: 74049150392     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2009.009284     Document Type: Review

References (62)

1. Apetrei C, Becker J, Metzger M, et al. Potential for HIV transmission through unsafe injections. AIDS 2006;20:1074-6
2. Rich J, Dickinson B, Carney J, Fisher A, Heimer R. Detection of HIV-1 nucleic acid and HIV-1 antibodies in needles and syringes used for non-intravenous injection. AIDS 1998;12:2345-50
3. Lopman B, French K, Baggaley R, Gregson S, Garnett G. HIV-contaminated syringes are not evidence of transmission. AIDS 2006;20:1905
4. Baggaley R, Boily M, White R, Alary M. Risk of HIV-1 transmission for parenteral exposure and blood transfusion: a systematic review and meta-analysis. AIDS 2006;20:805-12
5. Gisselquist D, Upham G, Potterat J. Efficiency of human immunodeficiency virus transmission through injections and other medical procedures: evidence, estimates, and unfinished business. Infect Control Hospital Epidemiol 2006;27:944-52
6. Hauri A, Armstrong G, Hutin Y. The global burden of disease attributable to contaminated injections given in health care settings. Int J STD AIDS 2004;15:7-16
7. Reid S. Increase in clinical prevalence of AIDS implies increase in unsafe medical injections. Int J STD AIDS 2009;20:295-9
8. Hersh BS, Popovici F. Acquired immunodeficiency syndrome in Romania. Lancet 1991;338:645-9
9. Vermeulen M, Lelie N, Sykes W, et al. Impact of individual-donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa. Transfusion 2009;49:1115-25
10. Bourinbaiar A. The ratio of defective HIV-1 particles to replication-competent infectious virions. Acta Virol 1994;38:59-61
11. Portner R. Animal Cell Biotechnology: Methods and Protocols. 2nd edn. New York: Humana Press, 2007
12. Phillips D. The role of cell-to-cell transmission in HIV infection. AIDS 1994;8:719-31
13. Bennett N, Howard R. Quantity of blood inoculated in a needlestick injury from suture needles. J Am Coll Surg 1994;178:107-10
14. CDC. How well does HIV survive outside the body? See http://www.cdc. gov/hiv/resources/qa/qa35.htm (last checked 9 July 2009)
15. Tjotta E, Hungnes O, Grinde B. Survival fo HIV-1 activity after disinfection, temperature and pH changes, or drying. J Med Virol 1991;35:223-7
16. Girard M, Eichberg J. Progress in the development of HIV vaccines. AIDS 1990;4(S1):S143-50
17. Spouge J. Statistical analysis of sparse infection data and its implications for retroviral treatment trials in primates. Proc Natl Acad Sci 1992;89:7581-5
18. Robert-Guroff M, Kaur H, Patterson J, et al. Vaccine protection against a heterologous, non-synctyium-inducing, primary human immunodeficiency virus. J Virol 1998;72:10275-80
19. Vyas G. Peripheral blood mononuclear cell substrate for an HIV-1 subunit vaccine: env-proteins derived from inactivated virions. New cells for New Vaccines III: from bench to Clinical Trials. IABS International Scientific Workshop; http://www.ibiopharma.com/adx/aspx/adGetMediaaspx?Doc ID=1107,1106,991,26,12,2,1,Documents&MediaID=1034&Filename=New+ cells+for+New+Vaccines+III+-+from+Lab+Bench+to+Clinical+Trials+(11-05-08).pdf (last accessed September 3, 2009) Wilmington, DI, 2008
20. Murthy K, Henrard D, Eichberg J, et al. Redefining the HIV-infectious window period in the chimpanzee model: evidence to suggest that viral nucleic acid testing can prevent blood-borne transmission. Transfusion 1999;39:688-93
21. Barre-Sinoussi F, Georges-Courbot M, Fultz P, et al. Characterization and titration of an HIV Type 1 Subtype E chimpanzee challenge stock. AIDS Res Hum Retroviruses 1997;13:583-91
22. Thompson J, Hu S, Kuller L, Travis B, Morton W, Agy M. SHIVIIIB infection of Macaca nemestrina: determination of a macaque infectious dose. Int Conf AIDS 1996;11:5 (Abstract no. We.A.142)
23. Wester C, Kim S, Biostat D, et al. Initial response to highly active antiretroviral therapy in HIV-1 C-infected adults in a public sector treatment program in Botswana. J Acquir Immune Defic Syndr 2005;40:336-43
24. Peter T, Novitsky V, Gaolekwe S, et al. Association Between Viral Load and CD4 Count in HIV-1 Subtype C Infection in Botswana. The International Conference on AIDS 2002 Jul 7-12;14:abstract no. TuPeC4815
25. Grobler J, Gray C, Rademeyer C, et al. Incidence of HIV-1 dual infection and its association with increased viral load set point in a cohort of HIV-1 subtype C-infected female sex workers. J Infect Dis 2004;190:1355-9
26. Abu-Raddad L, Patnaik P, Kublin J. Dual infection with HIV and malaria fuels the spread of both diseases in sub-Saharan Africa. Science 2006;314:1603-6
27. Ball S, Abraha A, Collins K, et al. Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C. J Virol 2003;77:1021-38
28. Marozsan A, Fraundorf E, Abraha A, et al. Relationships between infectious titer, capsid protein levels, and reverse transcriptase activities of diverse human immunodeficiency virus type 1 isolates. J Virol 2004;78:11130-41
29. Rusert P, Fischer M, Joos B, et al. Quantification of infectious HIV-1 plasma viral load using a boosted in vitro infection protocol. Virology 2004;326:113-29
30. Arien K, Gali Y, El-Abdellati A, Heyndrickx L, Janssens W, Vanham G. Replicative fitness of CCR5-using and CXCR4-using human immunodeficiency virus type 1 biological clones. Virology 2006;347:65-74
31. Lin Y, Mettling C, Portales P, Reynes J, Clot J, Corbeau P. Cell surface CCR5 density determines the postentry efficiency of R5 HIV-1 infection. Proc Natl Acad Sci USA 2002;99:15590-5
32. Cardo D, Culver D, Ciesielski C, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. N Engl J Med 1997;337:1485-90
33. Wittman A, Kralj N, Kover J, Gasthaus K, Phys D, Hofmann F. Study of blood contact in simulated surgical needlestick injuries with single or double latex gloving. Infect Control Hosp Epidemiol 2009;30:53-6
34. Gaughwin M, Gowans E, Ali R, Burrell C. Bloody needles: the volumes of blood transferred in simulations of needlestick injuries and shared use of syringes for injections of intravenous drugs. AIDS 1991;5:1025-7
35. Shirazian D, Herzlich B, Mokhtarian F, Grob D. Detection of HIV antibody and antigen (p24) in residual blood on needles and glass. Infect Control Hosp Epidemiol 1990;11:180-4
36. Mast S, Gerberding J, Sande M. Factors predicting infectivity following needlestick exposure to HIV: an in vitro model. Clin Res 1991;39:58A
37. Hoffman P, Larkin D. Needlestick and needleshare - the difference. J Infect Dis 1989;160:545
38. Napoli V, McGowan J. How much blood is in a needlestick? J Infect Dis 1987;155:828
39. Krikorian R, Lozach-Perlant A, Ferrier-Rembert A, et al. Standardization of needlestick injury and evaluation of a novel virus-inhibiting protective glove. J Hosp Infect 2007;66:339-45
40. Mast S, Woolwine J, Gerberding J. Efficacy of gloves in reducing blood volumes transferred during simulated needlestick injury. J Infect Dis 1993;168:1589-92
41. Shapshak P, Fujimura R, Page J, et al. HIV-1 RNA load in needles/syringes from shooting galleries in Miami: a preliminary laboratory report. Drug Alcohol Depend 2000;58:153-7
42. Hoelscher M, Riedner G, Hemed Y, Wagner H, Korte R, von Sonnenburg F. Estimating the number of HIV transmission through reused syringes and needles in the Mbeya Region, Tanzania. AIDS 1994;8:1609-15
43. Van Bueren J. Inactivation of human immunodeficiency virus type 1 by alcohols. J Hosp Infect 1994;28:137-48
44. Shisana O, Mehtar S, Mosala T, et al. HIV Risk Exposure Among Young Children: A Study of 2-9 Year Olds Served By Public Health Facilities in the Free State, South Africa. Cape Town, South Africa: Human Sciences Research Council, 2005
45. Abdala N, Stephens P, Griffith B, Heimer R. Survival of HIV-1 in syringes. J Acquir Immune Defic Syndr 1999;20:73-80
46. Heimer R, Abdala N. Viability of HIV-1 in syringes: implications for interventions among injection drug users. AIDS Reader 2000;10:410-7
47. Heimer R, Myers S, Cadman E, Kaplan E. Detection by polymerase chain reaction of human immunodeficiency virus type 1 proviral DNA sequences in needles of injecting drug users. J Infect Dis 1992;165:781-2
48. Abdala N, Gleghorn A, Carney J, Heimer R. Can HIV-1-contaminated syringes be disinfected? Implications for transmission among injection drug users. J Acquir Immune Defic Syndr 2001;28:487-94
49. Hersh BS, Popovici F. Acquired immunodeficiency syndrome in Romania. Lancet 1991;338:645-9
50. Kaplan E, Heimer R. A model-based estimate of HIV infectivity via needle sharing. J Acquir Immune Defic Syndr 1992;5:1116-8
51. Hudgens M, Longini I, Vanichseni S, et al. Subtype-specific transmission probabilities for human immunodeficiency virus among injecting drug users in Bangkok, Thailand. Am J Epidemiol 2002;155:159-68
52. Perlis T, Des Jarlais D, Friedman S, Kamyar A, Turner C. Audio-computerized self-interviewing verus face-to-face interviewing for research data collected at drug abuse treatment programs. Addiction 2004;99:885-96
53. Valente T, Vlahov D. Selective risk taking among needle exchange participants: implications for supplemental interventions. Am J Public Health 2001;91:406-11
54. Shaw S, Shah L, Jolly A, Wylie J. Determinants of injection drug user (IDU) syringe sharing: the relationships between availability of syringes and risk network member characteristics in Winnipeg, Canada. Addiction 2007;102:1626-35
55. Zhang L, Carruthers C, He T, et al. HIV type 1 subtypes, coreceptor usage, and CCR5 polymorphism. AIDS Res Hum Retroviruses 1997;13:1357-66
56. Moyle G, Wildfire A, Mandalia S, et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 2005;191:866-72
57. Clerici M, Butto S, Lukwiya M, et al. Immune activation in Africa is environmentally-driven and is associated with upregulation of CCR5. AIDS 2000;14:2083-92
58. Pope M, Haase A. Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. Nat Med 2003;9:847-52
59. Weber J. HIV and sexually transmitted disease. Br Med Bull 1998;54:717-29
60. Fang G, Kuiken C, Weiser B, et al. Long-term survivors in Nairobi: complete HIV-1 RNA sequences and immunogenetic associations. J Infect Dis 2004;190:699-701
61. Nokta M, Nichols J, Niles J, Pollard R. CCR5 and CXCR4 Cell Surface Density Correlated with HIV Plasma RNA and Markers Of Immune Activation in HIV Infected Individuals. The International Conference on AIDS 2000;13:Abstract no. TuPeA3085
62. Brenner B, Routy J, Petrella M, et al. Persistance and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol 2002;76:1753-61